Background
Welcome to the
Gonococcal Isolate Surveillance Project (GISP) homepage!
GISP was established in 1986 to monitor trends in antimicrobial
susceptibilities of strains of N. gonorrhoeae in the United
States in order to establish a rational basis for the selection of
gonococcal therapies. GISP is a collaborative project
between selected sexually transmitted diseases (STD) clinics, five
regional laboratories, and the Centers for Disease Control and
Prevention (CDC).
|
Overview of
Surveillance System
In GISP, N.
gonorrhoeae isolates are collected from the first 25 men with
urethral gonorrhea attending STD clinics each month in
approximately 28 cities in the United States. At regional
laboratories, the susceptibilities of these isolates to
penicillin, tetracycline, spectinomycin, ciprofloxacin,
ceftriaxone, cefixime, and azithromycin are determined by agar
dilution. Minimum inhibitory concentrations (MICs) are
measured, and values are interpreted according to criteria
recommended by the National Committee for Clinical Laboratory
Standards (NCCLS).
For more
information, please email: GISP
Coordinator (pzw5@cdc.gov)
The PDF
attachments on this website require Adobe reader.
Click on this button to download: |
|
|